Safety
Is BPC-157 legal? FDA status and the 2026 HHS policy
Is BPC-157 legal in 2026? It can be compounded on a prescription under an interim HHS policy. It is not FDA-approved, and research-use-only vials stay illegal.
By Julian Caraulani · Updated October 30, 2026 · Reviewed by Dr. A. Goher, MBBS
BPC-157 can legally be compounded on a prescription under an interim HHS policy published 30 October 2026, but it is not FDA-approved, and research-use-only BPC-157 sold for human use is still illegal. The policy covers state-licensed 503A pharmacies making single-peptide products for a named patient (Federal Register 2026-22192). States may set their own rules. Checked 30 Oct 2026.
The policy is interim and HHS can withdraw it. Compounded drugs are not FDA-approved. Below: where BPC-157 stands federally, what changed in 2026, why research vials are still a problem, and how to get it through a licensed program. For every peptide's status in one table, see the peptide legal status tracker.
BPC-157 legal status by situation (checked 30 Oct 2026)
| Situation | Federal status | Source |
|---|---|---|
| Prescribed by a clinician, made by a state-licensed 503A pharmacy, BPC-157 acetate as the only active ingredient, by a covered route | Within HHS's interim enforcement-discretion policy. Not FDA-approved | HHS policy |
| Covered routes | Subcutaneous, intramuscular, oral and topical | HHS policy, Appendix B |
| BPC-157 blended with TB-500 or another ingredient | Outside the policy: single active ingredient only | HHS policy |
| Made by a 503B outsourcing facility | Not addressed: the policy is written for 503A compounding | Federal Register |
| Research-use-only vial sold online for people to inject | FDA treats such products as unapproved drugs | FDA warning letter |
| FDA-approved BPC-157 product | None exists | FDA safety risks page |
Is BPC-157 FDA approved?
No. No BPC-157 drug has been approved by FDA, and the 2026 policy did not change that. The policy notice says so in general terms: "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" (Federal Register).
FDA's own scientists opposed adding BPC-157 to the list of substances pharmacies may use. HHS's appendix records that the "Center for Drug Evaluation and Research (CDER) recommended against listing either form, and the Pharmacy Compounding Advisory Committee (PCAC) voted in favor of inclusion" (HHS policy). The only use FDA evaluated for the July 2026 meeting was ulcerative colitis (Federal Register 2026-07361).
FDA's page on safety risks still carries its BPC-157 assessment: "FDA has identified no, or only limited, safety-related information for the proposed routes of administration" (FDA). Most of the research on BPC-157 is preclinical, and human data are thin; our BPC-157 side effects guide goes through what is known.
Price checked Oct 30 · Cancel anytime · Medication included · No email needed
What changed in 2026
BPC-157 spent two and a half years on FDA's Category 2 list, which marks substances FDA believed may present significant safety risks in compounding. HHS's appendix says BPC-157 free base and BPC-157 acetate "were in Category 2 from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A" (HHS policy). That last clause matters: dropping off Category 2 in April did not make BPC-157 compoundable, because it has no USP monograph, is not part of an approved drug, and is not on the 503A bulks list.
Then came three steps:
- 23 July 2026. FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 with KPV, TB-500 and MOTS-c (FDA meeting page). The committee voted in favor, per HHS. FDA had not posted minutes or a vote tally when we checked.
- 28 October 2026. HHS Secretary Robert F. Kennedy Jr. signed an enforcement-discretion policy, filed that day and published 30 October.
- Next. FDA rulemaking may or may not add BPC-157 to the 503A bulks list. The notice says "FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence" (Federal Register).
HHS gave three reasons for including BPC-157, one of them new evidence on quality: a lot-level certificate from an FDA-registered facility that, according to HHS, reports the identity, impurity, endotoxin, microbial and residual solvent results FDA's reviewers had found missing (HHS policy). For the full list of conditions, read the HHS peptide policy explained.
Why research-use-only BPC-157 is still illegal for human use
The policy covers pharmacies, not peptide sellers. HHS says its purpose is to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" (HHS policy). The ingredient a pharmacy uses must come from an FDA-registered maker with a certificate of analysis; a research vial has none of that chain.
FDA keeps sending warning letters to sellers who label injectables "research use only" while marketing them to people. In an August 2026 letter, FDA wrote that "evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA warning letter, TXP Innovations). We do not list research-use-only sellers. The differences are laid out in research vs prescription peptides.
Does the policy apply in every state?
The policy is a federal statement about federal enforcement. It says it "does not establish any rights for any person and is not binding on HHS or the public" (Federal Register). It does not change state pharmacy law. A state board of pharmacy can still restrict BPC-157, and some programs do not serve every state. Check your state on a program's own page before you pay.
Oral and topical BPC-157
Oral and topical BPC-157 acetate are covered routes, with an extra condition for oral products: the pharmacy "is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans" (HHS policy). Few programs offer oral BPC-157 yet. See oral vs injectable BPC-157.
How to get BPC-157 through a licensed program
A clinician reviews your history, writes a prescription if appropriate, and a licensed pharmacy compounds it. Prescription BPC-157 programs on this site start at $149 a month; every plan is on the BPC-157 price page. Superpower, from $149, took preorders the week the policy appeared and states on its page: "This interim policy provides conditional enforcement discretion for certain 503A-compounded peptides. It is not FDA approval" (Superpower). Our Superpower review covers what the price includes. We do not publish doses; your prescriber sets the form and amount.
FAQ
Is BPC-157 legal?
BPC-157 can be compounded by a state-licensed 503A pharmacy on a patient-specific prescription under an interim HHS policy published 30 October 2026, using BPC-157 acetate alone by subcutaneous, intramuscular, oral or topical routes. BPC-157 is not FDA-approved. Research-use-only vials marketed for people remain unapproved drugs in FDA's view. State rules can differ, and HHS can withdraw the policy. Checked 30 Oct 2026.
Is BPC-157 FDA approved?
No. FDA has never approved a BPC-157 drug. The 2026 change came from the HHS Secretary as a decision not to enforce against certain pharmacies, not from an FDA approval. HHS's own appendix records that FDA's drug center recommended against listing BPC-157, while the advisory committee voted in favor. Any page calling BPC-157 FDA-approved is wrong.
Is BPC-157 legal in 2026?
Federal status changed twice in 2026. BPC-157 left FDA's Category 2 list on 22 April 2026, which by itself did not permit compounding. On 30 October 2026, HHS published an interim policy saying it will not take enforcement action against 503A pharmacies compounding it under set conditions. Federal law on unapproved drugs, and state pharmacy law, still apply outside those conditions.
Can I legally use research-use-only BPC-157?
Research-use-only BPC-157 is outside the HHS policy, which covers pharmacy compounding on a prescription. FDA has warned sellers that research labels do not hide an intended human use, and HHS describes these foreign-made products as a safety risk. Nobody tests a research vial for you, so identity, purity and contamination are unknown. A prescription from a licensed program is the legal route.
Is oral BPC-157 legal?
Oral BPC-157 acetate is a covered route under the HHS policy, with an added condition. The compounding pharmacy must keep documentation showing that the specific oral formulation achieves adequate absorption in humans. Supplements or capsules sold without a prescription are not covered. Ask any program offering oral BPC-157 which pharmacy makes it and what absorption data it holds.
Is BPC-157 legal in every state?
Not necessarily. The HHS policy addresses federal enforcement only and is not binding on the public. State boards of pharmacy license and police pharmacies, and a state can restrict substances the federal government tolerates. Telehealth programs also choose which states to serve. Check a program's state list and ask your prescriber before paying.
Could BPC-157 become illegal to compound again?
Yes. HHS says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises. The policy also ends once FDA finalizes a rule that either adds BPC-157 to the 503A bulks list or leaves it off. A change in HHS leadership could also reverse it, since the policy creates no rights.
See every licensed BPC-157 program and its full monthly price on the BPC-157 cost page, or compare all programs on the best programs page.